Drug
Ipn01195
Ipn01195: highest development phase Phase 1/2, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| IPN01195 NCT06833008 | Phase 1/2 | Advanced Solid Tumor |
Latest
No recent events.
Follow Ipn01195 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.